A new approach for moving promising discoveries out of laboratories and into the hands of patients and physicians
With the “Valley of Death” looming as an increasingly serious obstacle to introducing better ways of preventing, diagnosing and treating diseases, a noted scientist today described a new approach for moving promising discoveries out of laboratories and into the hands of patients and physicians. He spoke at the 246th National Meeting & Exposition of the American Chemical Society, the world’s largest scientific society, being held here this week.
Dennis Liotta, Ph.D., cited widespread concern that innovative scientific discoveries, especially those resulting from billions of dollars in government investment in research, are withering on the vine rather than being translated into breakthrough new treatments.
“The Valley of Death is the place where potential new drugs all too often go to die,” said Liotta. “In drug development parlance, the Valley of Death refers to the obstacles that are keeping innovative medical research discoveries from becoming new drugs. Potential new drugs never even make it to clinical trials. We think we have an approach to bridge the valley.”
Liotta has been involved in moving 10 drugs into the hands of patients as medications approved by the U.S. Food and Drug Administration. Among them is the HIV drug Emtriva®, which was co-invented by Liotta, Raymond Schinazi and Woo-Baeg Choi and approved by the U.S. Food and Drug Administration in 2003. Emtriva® is now used in more than 90 percent of all HIV combination therapies prescribed around the world. In 2005, Emory University, where the drug was developed, sold its royalty interest in Emtriva® for $540 million to Gilead Sciences Inc.
The chances of a promising new discovery actually becoming a new drug always have been razor-slim, Liotta said. Hundreds of such discoveries happen each year, but only a handful of truly new medicines reach the market. Others are “me-too” drugs, similar to drugs approved in the past but in forms that have longer-lasting effects or with other minor improvements. But circumstances are making the Valley of Death even more hazardous, further reducing the movement of new compounds from lab to real-world remedies.
“Big pharmaceutical companies are cutting back on the kind of research and development activity needed to introduce truly new drugs,” Liotta said. “Research universities are the logical institutions to step in and complement the work in private industry. Dozens of universities have such programs, but with a focus that makes it difficult for them to move a potential new drug forward to the point of clinical trials.”
To fill that gap, Emory used $30 million from the royalty sale of Emtriva® to form two nonprofits: Drug Innovation Ventures at Emory (DRIVE) and the Emory Institute for Drug Development (EIDD). DRIVE’s goal is to invest in discoveries with the potential to become new drugs. In effect, DRIVE is the “industrial partner” of the EIDD, organized as a virtual drug development company with a highly experienced management team. As a nonprofit, DRIVE can license attractive development opportunities from Emory or elsewhere on commercially favorable terms.
“With either its own seed capital or external funds, DRIVE then can use EIDD or external vendors to move these opportunities quickly and efficiently down the development continuum to meet the critical need for new therapeutic agents to treat infectious diseases,” Liotta said.
The Latest Bing News on:
- At 3.85% CAGR, Antifungal Drug Market Size will reach 14.27 billion Mn US$ by 2025on June 29, 2020 at 2:28 pm
Selbyville, Delaware: Market Study Report adds global Antifungal Drug market report that gives meticulous investigation of current scenario of the market size, share, demand, growth, trends, companies ...
- Breakingviews - Gilead gives glimpse into feverish drug marketon June 29, 2020 at 1:41 pm
Medicine may be a science but drug pricing is definitely an art. That’s especially true of Gilead Sciences’ treatment for Covid-19, given the lack of alternative treatments for a pandemic. The $2,300 ...
- Oncopeptides Strengthens the Pre-clinical Development and Takes over Kancera's Solna-based Laboratory for Drug Development as of July 1on June 29, 2020 at 9:00 am
Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Company has agreed with Kancera to take over Kancera's drug development facility in Solna, Sweden.
- Thermo Scientific workflow aims to accelerate drug developmenton June 29, 2020 at 7:01 am
The iSPA Workflow, using single-particle analysis technology, is intended to help pharmaceutical bring drugs to market faster while conserving costs.
- FDA gets 360-degree view of drug-development life cycle after eliminating data siloson June 25, 2020 at 8:18 am
Seven years ago, the FDA desired to get a handle on its vast data in order to achieve a full 360-degree view of the drug-development life cycle, according to Shanthi Vigneshwaran (pictured), ...
- Academy of Finland funds projects for vaccine and drug development for COVID-19on June 25, 2020 at 7:21 am
The Academy of Finland has selected the projects to be funded from the call for research into COVID-19 vaccines and pharmaceutical development.
- Virtual clinical trials now being used to fast-track drug development during coronavirus crisison June 25, 2020 at 5:51 am
Eager to streamline the process of drug development during the pandemic, researchers, pharmaceutical companies and a handful of tech start-ups have started virtual clinical trials, also known as ...
- Immunotherapy Drugs Market Development Status, Emerging Technologies, Regional Trends and Comprehensive Research Study 2025on June 25, 2020 at 5:32 am
This market research report includes a detailed segmentation of the global immunotherapy drugs market by drug type (monoclonal antibodies, vaccine, non-specific immunotherapies, adaptive cell therapy, ...
- FDA finalizes bacterial pneumonia drug development guidanceson June 24, 2020 at 1:09 pm
The US Food and Drug Administration (FDA) on Wednesday finalized two guidances on developing drugs to treat community-acquired or hospital-acquired and ventilator-associated bacterial pneumonia.
- NanoViricides Signs Memorandum of Understanding for Human Coronavirus Drug Development Licenseon June 9, 2020 at 3:18 am
NanoViricides has been working on drug development to treat the SARS-CoV-2 infection in COVID-19 patients since January, 2020. Prior to this, the Company had engaged in limited research and ...
The Latest Google Headlines on:
The Latest Bing News on:
New drug discovery
- Pharma’s Dirty Secret, And The Synthetic Biology Startup Offering A New Approachon June 29, 2020 at 5:17 am
Many of today’s most trusted drugs are so notorious for their wide range of potentially serious adverse reactions, they are known in the business as “dirty drugs.” Synthetic biology company Octant Bio ...
- Old Drugs Could Reveal a New Way to Attack the Coronaviruson June 27, 2020 at 4:00 am
Researchers found that SARS-CoV-2 hijacks tendrils that grow from infected cells and may ride them to infect others. But existing compounds might slow their roll.
- High-Performance Cloud Speeds Drug Discovery And Moreon June 25, 2020 at 2:08 am
GridMarkets runs its rendering platform on Oracle Cloud Infrastructure, speeding production of ultraheavy workloads at scale.
- New virtual incubator can catalyze early-stage drug discovery and developmenton June 24, 2020 at 7:41 am
Samsara BioCapital, a leading life sciences investment firm, Evotec SE, a global drug discovery alliance and development partnership company (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: ...
- Small Molecule Drug Discovery Market Report Examines Analysis by Latest Trends, Growth Factors, Key Players and Forecast to 2028on June 24, 2020 at 4:45 am
3) Identification of new market opportunities and targeted consumer marketing strategies for global small molecule drug discovery market. 4) Analysis of R&D and demand for new technologies and new ...
- Samsara, Evotec, KCK launch Autobahn Labs, a novel early stage drug discovery incubatoron June 24, 2020 at 4:21 am
Samsara BioCapital, a leading life sciences investment firm, Evotec SE, a global drug discovery alliance and development partnership company and KCK Ltd., a family investment fund, today announced the ...
- Samsara BioCapital, Evotec and KCK Launch Autobahn Labs, a Novel Early Stage Drug Discovery Incubatoron June 24, 2020 at 4:00 am
Samsara BioCapital, a leading life sciences investment firm, Evotec SE, a global drug discovery alliance and development partnership ...
- TARA Biosystems Announces $10 Million Series A2 Financing to Expand its Cardiac Disease Drug Discovery and Development Capabilitieson June 23, 2020 at 1:52 pm
TARA Biosystems, Inc., a company generating in vitro human biology to increase the success of cardiac disease drug discovery and development, today announced a $10 million Series A2 financing. This fi ...
- Schrödinger Announces Advanced COVID-19 Drug Discovery Efforts with Google Cloudon June 23, 2020 at 8:24 am
Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and ...
- Schrödinger Announces Strategic Collaboration With Thermo Fisher Scientific to Expand Structure-Based Drug Discovery to Novel Targets Using Cryo-EMon June 23, 2020 at 5:37 am
Schrödinger (Nasdaq:SDGR) today announced a strategic collaboration with Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug ...